Rationale and design of the LosmApimod To Inhibit p38 MAP kinase as a TherapeUtic target and moDify outcomes after an acute coronary syndromE trial

Michelle L O'Donoghue, Ruchira Glaser, Philip E Aylward, Matthew A Cavender, Adam Crisp, Keith A A Fox, Ian Laws, Jose L Lopez-Sendon, P Gabriel Steg, Pierre Theroux, Marc S Sabatine, David A Morrow

Research output: Contribution to journalArticlepeer-review

Abstract / Description of output

BACKGROUND: p38 mitogen-activated protein kinase (MAPK) mediates cytokine production and amplification of the inflammatory cascade. Through inhibition of p38 MAPK, losmapimod appears to attenuate the inflammatory response in the vascular wall and thus may help stabilize plaques.

STUDY DESIGN: The LATITUDE-TIMI 60 trial is a randomized, double-blind, placebo-controlled, parallel-group, multicenter study planned to be conducted in a 3-stage design. Overall, the trial is designed to include 25,500 patients hospitalized with non-ST-elevation or ST-elevation myocardial infarction (MI) randomized to oral losmapimod (7.5 mg twice daily) versus matching placebo. Part A consists of a leading cohort (n = 3,500) that will provide an initial assessment of safety and exploratory efficacy before progressing to part B. Part B (n = ~22,000) of the study is event driven and will provide the primary assessment of efficacy. An independent safety review will be conducted after 3,500 patients in part B1 to determine whether a more focused schedule of clinic visits and laboratory assessments can be implemented (part B2). All patients are to be treated with study drug until week 12 and followed up until week 24. The primary end point is the composite of cardiovascular death, MI, or severe recurrent ischemia requiring urgent coronary revascularization. The key secondary end point is the composite of cardiovascular death or MI. The trial is designed to provide ≥90% power for the primary end point.

CONCLUSIONS: The LATITUDE-TIMI 60 trial will determine the efficacy and safety of short-term p38 MAPK inhibition with losmapimod in acute MI. The trial design adopts a stepwise approach to decision making and collection of data.

Original languageEnglish
Pages (from-to)622-630.e6
JournalAmerican Heart Journal
Issue number5
Publication statusPublished - May 2015

Keywords / Materials (for Non-textual outputs)

  • Acute Coronary Syndrome
  • Adult
  • Cyclopropanes
  • Double-Blind Method
  • Female
  • Humans
  • Male
  • Middle Aged
  • Placebos
  • Protein Kinase Inhibitors
  • Pyridines
  • Research Design
  • p38 Mitogen-Activated Protein Kinases


Dive into the research topics of 'Rationale and design of the LosmApimod To Inhibit p38 MAP kinase as a TherapeUtic target and moDify outcomes after an acute coronary syndromE trial'. Together they form a unique fingerprint.

Cite this